Oxolife Appoints International Fertility Experts to its Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Infertility - not being able to conceive despite having regular unprotected sex for a year - affects one in seven UK couples. Here, we look at some of the most promising options for budding mothers.
Embryo Screening: The Story Of Germany s First PGD Baby worldcrunch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from worldcrunch.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for .
ObsEva SAAugust 4, 2021 GMT
-
s
-
Published
-
Geneva, Switzerland and Boston, MA – August 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF).
ADVERTISEMENT
Human Reproduction. The study reports the results from a meta-analysis of three randomized, placebo-controlled trials showing that nolasiban increased the likelihood of live birth following IVF. Participants were administered a single oral dose of nolasiban 900 mg (n=846) or placebo (n=864) and